About US
Contact us
-
ASCO: J&J pads case for new Erleada use with prostate cancer survival dataCHICAGO—Johnson & Johnson’s Erleada may be thefollow-up to blockbuster Zytiga, but it’s also ready to go where its predecessor hasn’t gone before. Friday at the American Society of Clinical Oncol2019/6/3
-
ASCO: Merck details Keytruda's second stomach cancer slipCHICAGO—Last month, Merck revealed that its Keytruda immunotherapy had run into more trouble in stomach cancer, a disease that’s given it difficultyin the past. And it shared the details of that stum2019/6/3
-
ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survivalCHICAGO—Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed Keytruda could produce. At t2019/5/31
-
ASCO: Novartis' Kisqali posts first-in-class survival win in younger womenCHICAGO—Even before it launched, Novartis’ Kisqali was living in the shadow of classmate Ibrance, and it has been ever since. But with its latest data set, Kisqali now has an advantage the Pfizer blo2019/5/31
-
ASCO: Pfizer, Astellas' Xtandi racks up more data for new prostate cancer approvalCHICAGO—Pfizer and Astellas’ Xtandi is gunning for a new indication in prostate cancer, and they say Sunday's new data complement the supporting evidence they’ve already generated. Sunday at the Amer2019/5/30
-
ASCO: Gilead touts CAR-T franchise with Yescarta analyses, early data on pipeline drugAs other parts of its business slump, Gilead Sciences has zeroed in on cell therapy, hoping to lead a wave into that new market. And at the American Society of Clinical Oncology's (ASCO's) annual m2019/5/30
-
All the ASCO skinny: Lynparza's pancreatic win, Amgen's KRAS spotlight, Merck's history-busting and moreThe cancer world flocked to Chicago over the weekend for what's traditionally been the biggest oncology meet-up of the year. But this year's American Society of Clinical Oncology line-up didn't exact2019/5/29
-
ASCO: AZ, Merck's Lynparza fends off pancreatic cancer, cutting progression risk in halfCHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology (ASCO) annual meeting—and doing it in some of the toughest-to-trea2019/5/29
-
Four pharma firms accused of anti-competitive practices in UKThe UK Competition and Markets Authority (CMA) has accused Alliance Pharmaceuticals, Focus, Lexon and Medreich of avoiding competition for anti-nausea drug, prochlorperazine. Indicated for the treatm2019/5/28
-
Lilly starts selling half-price version of Humalog insulinEli Lilly has announced the market launch of a half-price, generic version of its Humalog insulin. Called Insulin Lispro Injection, the product is available in a vial or within a KwikPen. Insulin Lis2019/5/28